Safety and Efficacy of TUDCA as add-on Treatment in Patients Affected by ALS
Status:
Recruiting
Trial end date:
2022-12-30
Target enrollment:
Participant gender:
Summary
This is a Phase III, multi-centre, randomized, double-blind, placebo-controlled,
parallel-group study to evaluate Safety and Efficacy of Tauroursodeoxycholic (TUDCA) as
add-on Treatment in Patients Affected by Amyotrophic Lateral Sclerosis (ALS).
Phase:
Phase 3
Details
Lead Sponsor:
Humanitas Mirasole SpA
Collaborators:
Bruschettini S.r.l. European Commission Istituto Superiore di Sanità KU Leuven Motor Neurone Disease Association UMC Utrecht University Hospital, Tours University of Dublin, Trinity College University of Sheffield University of Ulm